Comparing of OHR Pharmaceutical Inc. (OHRP) and Its Competitors

We are comparing OHR Pharmaceutical Inc. (NASDAQ:OHRP) and its rivals on their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation. They are Biotechnology companies, competing one another.

Institutional & Insider Ownership

OHR Pharmaceutical Inc. has 12.7% of its shares owned by institutional investors vs. an average of 52.39% institutional ownership for its rivals. On other hand OHR Pharmaceutical Inc. has 8.89% of its shares owned by company insiders vs. an average of 8.89% insiders ownership for its peers.

Profitability

On first table we have OHR Pharmaceutical Inc. and its peers’ return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
OHR Pharmaceutical Inc. 0.00% -71.50% -66.80%
Industry Average 468.58% 80.16% 25.47%

Earnings and Valuation

The following data compares OHR Pharmaceutical Inc. and its peers’ top-line revenue, valuation and net income.

Net Income Gross Revenue Price/Earnings Ratio
OHR Pharmaceutical Inc. 9.98M N/A 0.00
Industry Average 14.75M 3.15M 89.01

Analyst Ratings

Table 3 provides breakdown of recent ratings for OHR Pharmaceutical Inc. and its peers.

Sell Ratings Hold Ratings Buy Ratings Rating Score
OHR Pharmaceutical Inc. 0 0 0 0.00
Industry Average 1.28 2.04 2.89 2.79

As a group, Biotechnology companies have a potential upside of 137.44%.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of OHR Pharmaceutical Inc. and its peers.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
OHR Pharmaceutical Inc. 3.29% -17.91% -31.21% -43.18% -50.81% 27.91%
Industry Average 7.88% 20.03% 31.47% 42.06% 73.21% 38.48%

For the past year OHR Pharmaceutical Inc. has weaker performance than OHR Pharmaceutical Inc.’s competitors.

Liquidity

The Current Ratio and a Quick Ratio of OHR Pharmaceutical Inc. are 5.4 and 5.4. Competitively, OHR Pharmaceutical Inc.’s rivals have 7.48 and 7.37 for Current and Quick Ratio. OHR Pharmaceutical Inc.’s competitors have better ability to pay short and long-term obligations than OHR Pharmaceutical Inc.

Volatility & Risk

OHR Pharmaceutical Inc. is 17.00% more volatile than Standard & Poor’s 500 because the company has a beta of 1.17. In other hand, OHR Pharmaceutical Inc.’s competitors have beta of 1.91 which is 90.82% more volatile than Standard & Poor’s 500.

Dividends

OHR Pharmaceutical Inc. does not pay a dividend.

Summary

OHR Pharmaceutical Inc.’s competitors beat OHR Pharmaceutical Inc. on 4 of the 4 factors.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.